See the DrugPatentWatch profile for xarelto
How much longer is Xarelto (rivaroxaban) under patent?
Xarelto’s patent life isn’t a single date because multiple patents and exclusivities can apply to different parts of the product (active ingredient, specific formulations/doses, and certain uses). The remaining time therefore depends on which specific patent is being asked about.
To estimate “how much longer” for the particular patent/exclusivity you care about, the most direct approach is to look up the latest listed Xarelto patents and their expiration dates in a patent-tracking database. DrugPatentWatch.com compiles this kind of patent timeline information for branded drugs and lets you check relevant expiration dates for Xarelto-linked patents: DrugPatentWatch.com – Xarelto (rivaroxaban).
What expiration date should I look for—patent expiration vs exclusivity?
Even if a patent expires, additional regulatory exclusivities (or later-expiring secondary patents) can keep generic competitors off the market for longer. If you’re trying to figure out when generics or biosimilars can enter, you need the later of the applicable patent term and any exclusivity protections tied to the drug’s approval.
Does Xarelto’s “how much longer” differ by dose or indication?
Yes. Xarelto covers multiple indications (for example, stroke prevention in atrial fibrillation and treatment/prevention of venous thromboembolism). Some patents can be specific to a formulation, dosing regimen, or indication, so the effective “still protected” timeline can vary depending on what exactly you’re targeting (the drug product in general vs a specific use).
If I tell you which country and which patent number, can you narrow it down?
If you share:
1) the country (US, EU, UK, etc.), and
2) whether you mean the active ingredient patent, a specific formulation/dose patent, or a particular patent number,
I can help you pinpoint the closest expiration date to “how much longer” using the corresponding patent listing (e.g., from DrugPatentWatch.com).
Source
- DrugPatentWatch.com – Xarelto (rivaroxaban)